The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

A photothermal, nanoparticle-based deep brain stimulation system restored motor skills in mice with Parkinson’s-like disease ...

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eight canines were randomized into two groups who received 0.5mg of semaglutide delivered via oral administration of the RaniPill ® HC (N=4) or subcutaneous injection (N=4). Endpoints included plasma ...

The drug, amycretin, is a peptide designed to bind to and activate both the GLP-1 and amylin receptors. Novo Nordisk is developing the molecule for the treatment of obesity and type 2 diabetes ...